New Era of Preventing End-Stage Kidney Disease Act

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.6790, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. H.R.6790, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, The New Eras of Preventing End-Stage Kidney Disease Act (HR 6790) and rare nephrology issues, 340B reform, Psychedelics treatments for PTSD and mental health, and BIOSECURE Act.

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.6790, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act

Client expense: $140,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM reform, The New Eras of Preventing End-Stage Kidney Disease Act (HR 6790), 340B reform, FY2025 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD), FY2025 Agriculture, FDA, and Related Agencies Appropriations (box warning report language), FY2025 MilCon VA Appropriations (PTSD screening), FY2025 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD), and BIOSECURE Act.

Client expense: $340,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.6790, New Era of Preventing End-Stage Kidney Disease Act.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.6790, New Era of Preventing End-Stage Kidney Disease Act.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act

Client expense: $105,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE